ATE402921T1 - Cyclische amine mit einem heterocyclischen substituenten als bace-1-inhibitoren - Google Patents

Cyclische amine mit einem heterocyclischen substituenten als bace-1-inhibitoren

Info

Publication number
ATE402921T1
ATE402921T1 AT04780561T AT04780561T ATE402921T1 AT E402921 T1 ATE402921 T1 AT E402921T1 AT 04780561 T AT04780561 T AT 04780561T AT 04780561 T AT04780561 T AT 04780561T AT E402921 T1 ATE402921 T1 AT E402921T1
Authority
AT
Austria
Prior art keywords
bace
inhibitors
cyclic amine
heterocyclic substituent
heterocyclic
Prior art date
Application number
AT04780561T
Other languages
English (en)
Inventor
Jared Cumming
Ying Huang
Guoqing Li
Ulrich Iserloh
Andrew Stamford
Corey Strickland
Johannes Voigt
Yusheng Wu
Jianping Pan
Tao Guo
Douglas Hobbs
Thuy Le
Jeffrey Lowrie
Original Assignee
Schering Corp
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp
Application granted granted Critical
Publication of ATE402921T1 publication Critical patent/ATE402921T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Structural Engineering (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT04780561T 2003-08-08 2004-08-04 Cyclische amine mit einem heterocyclischen substituenten als bace-1-inhibitoren ATE402921T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49364603P 2003-08-08 2003-08-08

Publications (1)

Publication Number Publication Date
ATE402921T1 true ATE402921T1 (de) 2008-08-15

Family

ID=34135273

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04780561T ATE402921T1 (de) 2003-08-08 2004-08-04 Cyclische amine mit einem heterocyclischen substituenten als bace-1-inhibitoren

Country Status (17)

Country Link
US (2) US7598250B2 (de)
EP (1) EP1660447B1 (de)
JP (2) JP4472700B2 (de)
KR (1) KR20060056376A (de)
CN (1) CN1863770B (de)
AR (1) AR045219A1 (de)
AT (1) ATE402921T1 (de)
AU (1) AU2004263532A1 (de)
CA (1) CA2534672A1 (de)
DE (1) DE602004015476D1 (de)
ES (1) ES2308247T3 (de)
IL (1) IL173534A0 (de)
MX (1) MXPA06001558A (de)
PE (1) PE20050354A1 (de)
TW (1) TW200524910A (de)
WO (1) WO2005014540A1 (de)
ZA (1) ZA200601101B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
WO2005087752A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
CA2558034A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
EP1740573A1 (de) 2004-04-22 2007-01-10 Eli Lilly And Company Amide als bace-inhibitoren
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
EP1745018A1 (de) * 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibitoren des azetidinglycintransporters
JP2008502684A (ja) 2004-06-15 2008-01-31 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのベータ−セクレターゼ阻害剤として有用なピロリジン−3−イル化合物
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
AU2005265354A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
CA2576782A1 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors
CA2577392A1 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
AU2005286844A1 (en) * 2004-09-17 2006-03-30 Comentis, Inc Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
JP2008535863A (ja) 2005-04-08 2008-09-04 コメンティス,インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
ATE482214T1 (de) 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
JP2009511589A (ja) * 2005-10-12 2009-03-19 エラン ファーマシューティカルズ,インコーポレイテッド アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
CN101346357B (zh) * 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
JP2009515964A (ja) * 2005-11-16 2009-04-16 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのβ−セクレターゼ阻害剤として有用なイミダゾリジノン化合物
US8168641B2 (en) 2006-06-12 2012-05-01 Schering Corporation Aspartyl protease inhibitors
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
MX2010000956A (es) * 2007-07-26 2010-03-01 Comentis Inc Derivados de isoftalamida que inhiben actividad de beta-secretasa.
CN101848897A (zh) 2007-09-06 2010-09-29 先灵公司 γ分泌酶调节剂
WO2009061699A1 (en) 2007-11-05 2009-05-14 Schering Corporation Gamma secretase modulators
CA2708300A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
EP2323735A1 (de) 2008-07-29 2011-05-25 Alcobra Ltd. Substituierte pyridoxin-lactam-carboxylat-salze
WO2010054067A1 (en) * 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
AU2009314049B2 (en) 2008-11-13 2015-03-05 Merck Sharp & Dohme Corp. Gamma secretase modulators
JP2012513399A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
EP2379566A2 (de) 2008-12-22 2011-10-26 Schering Corporation Modulatoren von gamma-sekretase
US20120214802A1 (en) * 2009-03-25 2012-08-23 Bilcer Geoffrey M Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443118A1 (de) 2009-06-16 2012-04-25 Schering Corporation Gammasekretasemodulatoren
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485591B1 (de) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazindioxinverbindungen als bace-hemmer, zusammensetzungen und ihre verwendung
EP2485920B1 (de) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Heterozyklische pentafluorsulfur-imin-verbindungen als bace-1-hemmer sowie zusammensetzungen damit und ihre verwendung
EP2694489B1 (de) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6-oxacyclus-fusionierte thiadiazindioxidverbindungen als bace-hemmer sowie zusammensetzungen daraus und ihre verwendung
AU2012266544A1 (en) * 2011-06-07 2013-11-21 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
HK1211589A1 (zh) 2012-08-23 2016-05-27 Alios Biopharma, Inc. 用於治疗副粘病毒病毒性感染的化合物
EP2908824B1 (de) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclische substituierte thiadiazindioxidverbindungen als bace-hemmer, zusammensetzungen und deren verwendung
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
HK1225716A1 (zh) 2013-08-21 2017-09-15 Alios Biopharma, Inc. 抗病毒化合物
US9745324B2 (en) 2013-12-18 2017-08-29 Merck Sharp & Dohme Corp. Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
US10968176B2 (en) 2014-09-14 2021-04-06 Nanosynthons Llc Pyrrolidone derivatives, oligomers and polymers
EP3194365A4 (de) * 2014-09-14 2018-04-25 Nanosynthons LLC Pyrrolidonderivate, oligomere und polymere
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング,インコーポレイテッド Tim-3とそのリガンドとの相互作用の遮断によるがん治療
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CN109942446B (zh) * 2019-04-17 2021-09-07 黄冈鲁班药业股份有限公司 一种普瑞巴林的制备方法
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング,インコーポレイテッド ガレクチン-3を遮断することにより炎症性疾患を処置する方法
WO2025224139A1 (en) * 2024-04-24 2025-10-30 Specialty Operations France 2-piperidinone derivatives and their use as solvents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003842A1 (en) 1987-10-21 1989-05-05 The Upjohn Company Renin inhibitors containing a (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety
TW282460B (de) 1993-12-28 1996-08-01 Yamanouchi Pharma Co Ltd
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
EP1159263A1 (de) 1999-02-26 2001-12-05 Merck & Co., Inc. Sulfonamid-verbindungen und anwendungen davon
JP2002539260A (ja) * 1999-03-24 2002-11-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アスパルチルプロテアーゼインヒビターを使用して神経変性障害を処置する方法
TW520575B (en) * 2000-04-21 2003-02-11 Sony Corp Positive electrode material and nickel-zinc battery
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
DE60116313T2 (de) * 2000-06-30 2006-08-31 Elan Pharmaceuticals, Inc., San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
ATE515495T1 (de) * 2001-08-03 2011-07-15 Schering Corp Gamma sekretase inhibitoren
MXPA04001016A (es) 2001-08-03 2004-05-27 Schering Corp Derivados de sulfonamida como inhibidores de la gamma secretasa.
HUP0401241A3 (en) 2001-08-21 2008-03-28 Merck Sharp & Dohme Novel cyclohexyl sulphones, process for their preparation and pharmaceutical compositions containing them
AU2002356525A1 (en) * 2001-09-24 2003-04-07 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
AR037460A1 (es) * 2001-11-30 2004-11-10 Smithkline Beecham Plc Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
TW200302717A (en) 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors

Also Published As

Publication number Publication date
JP2007501803A (ja) 2007-02-01
DE602004015476D1 (de) 2008-09-11
AR045219A1 (es) 2005-10-19
TW200524910A (en) 2005-08-01
EP1660447A1 (de) 2006-05-31
ZA200601101B (en) 2007-05-30
US20050043290A1 (en) 2005-02-24
AU2004263532A1 (en) 2005-02-17
KR20060056376A (ko) 2006-05-24
JP4472700B2 (ja) 2010-06-02
ES2308247T3 (es) 2008-12-01
WO2005014540A1 (en) 2005-02-17
US20090312341A1 (en) 2009-12-17
CN1863770A (zh) 2006-11-15
US7598250B2 (en) 2009-10-06
EP1660447B1 (de) 2008-07-30
CA2534672A1 (en) 2005-02-17
IL173534A0 (en) 2006-07-05
CN1863770B (zh) 2011-05-25
PE20050354A1 (es) 2005-05-17
JP2010047610A (ja) 2010-03-04
MXPA06001558A (es) 2006-05-15
US7910590B2 (en) 2011-03-22

Similar Documents

Publication Publication Date Title
ATE402921T1 (de) Cyclische amine mit einem heterocyclischen substituenten als bace-1-inhibitoren
ATE424383T1 (de) Cyclische amine mit benzamidsubstituent als bace- 1-inhibitoren
ATE494287T1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
IS7599A (is) Heterósýklískir kínasatálmar
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE452635T1 (de) Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE501138T1 (de) Thiophenderivate als chk-1-inhibitoren
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE521607T1 (de) Piperidinderivate als renin-inhibitoren
DK1919907T3 (da) Heterocyklisk forbindelse
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE443054T1 (de) Cyano-pyrrolidine als dpp-iv inhibitoren
DE602004017623D1 (de) N-substituierte pyrazolyl-amidyl-benzimidazolyl-c-kit-inhibitoren
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
ATE500227T1 (de) Amidderivate
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties